FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377011059> ?p ?o ?g. }

• W4377011059 endingPage "915" @default.
• W4377011059 startingPage "901" @default.
• W4377011059 abstract "Upadacitinib (UPA) is an oral, selective Janus kinase inhibitor that has demonstrated favorable efficacy with an acceptable safety profile across a global, phase 3 program in rheumatoid arthritis (RA). This phase 2 open-label extension investigated the efficacy and safety of UPA through 6 years of treatment. Patients from two phase 2b trials (BALANCE-1 and -2) enrolled in BALANCE-EXTEND (NCT02049138) and received open-label UPA 6 mg twice daily (BID). Dose increases to 12 mg BID were required for patients with < 20% improvement in swollen or tender joint counts at weeks 6 or 12 and permitted for those not achieving Clinical Disease Activity Index (CDAI) low disease activity (LDA; CDAI 2.8 to ≤ 10). Dose reduction to UPA 6 mg BID was permitted only for safety or tolerability reasons. After January 2017, the 6/12 mg BID doses were replaced by 15/30 mg once-daily extended-release equivalents. Efficacy and safety were monitored up to 6 years of UPA treatment; outcomes included rates of achievement of LDA or remission. Data were analyzed for patients who received the lower UPA dose throughout; titrated up to the higher UPA dose from weeks 6 or 12; or titrated to the higher UPA dose and back down. Overall, 493 patients entered BALANCE-EXTEND (‘Never titrated’, n = 306; ‘Titrated up’, n = 149; ‘Titrated up and down’, n = 38), and 223 patients (45%) completed the 6-year study. Total cumulative exposure was 1863 patient-years. Rates of LDA and remission were maintained through 6 years. Overall, 87%/70%/73% of patients in the ‘Never titrated’/‘Titrated up’/‘Titrated up and down’ groups achieved CDAI LDA at week 312, while the respective rates of Disease Activity Score 28 with C-reactive protein meeting LDA and remission criteria were 85%/69%/70% and 72%/46%/63%. Improvements in patient-reported outcomes were similar among the three groups. No new safety signals were identified. In this open-label extension of two phase 2 studies, UPA demonstrated sustained efficacy and an acceptable safety profile through 6 years of treatment in patients who completed the study. These data support a favorable long-term benefit–risk profile of UPA in patients with RA. Trial registration number: NCT02049138." @default.
• W4377011059 created "2023-05-19" @default.
• W4377011059 creator A5014591095 @default.
• W4377011059 creator A5019605448 @default.
• W4377011059 creator A5021102788 @default.
• W4377011059 creator A5022234929 @default.
• W4377011059 creator A5025636766 @default.
• W4377011059 creator A5028615814 @default.
• W4377011059 creator A5059585172 @default.
• W4377011059 creator A5082669130 @default.
• W4377011059 creator A5083576726 @default.
• W4377011059 creator A5086044066 @default.
• W4377011059 creator A5087011306 @default.
• W4377011059 date "2023-05-18" @default.
• W4377011059 modified "2023-10-11" @default.
• W4377011059 title "Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study" @default.
• W4377011059 cites W1979364075 @default.
• W4377011059 cites W2120393706 @default.
• W4377011059 cites W2147285403 @default.
• W4377011059 cites W2314052274 @default.
• W4377011059 cites W2559407770 @default.
• W4377011059 cites W2559743688 @default.
• W4377011059 cites W2807791746 @default.
• W4377011059 cites W2808333862 @default.
• W4377011059 cites W2946233321 @default.
• W4377011059 cites W2965035961 @default.
• W4377011059 cites W3041856700 @default.
• W4377011059 cites W3092992115 @default.
• W4377011059 cites W3103661543 @default.
• W4377011059 cites W3171954900 @default.
• W4377011059 cites W4210657972 @default.
• W4377011059 cites W4231972505 @default.
• W4377011059 cites W4283704737 @default.
• W4377011059 cites W4296696831 @default.
• W4377011059 doi "https://doi.org/10.1007/s40744-023-00557-x" @default.
• W4377011059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37199884" @default.
• W4377011059 hasPublicationYear "2023" @default.
• W4377011059 type Work @default.
• W4377011059 citedByCount "0" @default.
• W4377011059 crossrefType "journal-article" @default.
• W4377011059 hasAuthorship W4377011059A5014591095 @default.
• W4377011059 hasAuthorship W4377011059A5019605448 @default.
• W4377011059 hasAuthorship W4377011059A5021102788 @default.
• W4377011059 hasAuthorship W4377011059A5022234929 @default.
• W4377011059 hasAuthorship W4377011059A5025636766 @default.
• W4377011059 hasAuthorship W4377011059A5028615814 @default.
• W4377011059 hasAuthorship W4377011059A5059585172 @default.
• W4377011059 hasAuthorship W4377011059A5082669130 @default.
• W4377011059 hasAuthorship W4377011059A5083576726 @default.
• W4377011059 hasAuthorship W4377011059A5086044066 @default.
• W4377011059 hasAuthorship W4377011059A5087011306 @default.
• W4377011059 hasBestOaLocation W43770110591 @default.
• W4377011059 hasConcept C126322002 @default.
• W4377011059 hasConcept C197934379 @default.
• W4377011059 hasConcept C2776233030 @default.
• W4377011059 hasConcept C2777575956 @default.
• W4377011059 hasConcept C2778375690 @default.
• W4377011059 hasConcept C2778886723 @default.
• W4377011059 hasConcept C3018359032 @default.
• W4377011059 hasConcept C3019800554 @default.
• W4377011059 hasConcept C71924100 @default.
• W4377011059 hasConceptScore W4377011059C126322002 @default.
• W4377011059 hasConceptScore W4377011059C197934379 @default.
• W4377011059 hasConceptScore W4377011059C2776233030 @default.
• W4377011059 hasConceptScore W4377011059C2777575956 @default.
• W4377011059 hasConceptScore W4377011059C2778375690 @default.
• W4377011059 hasConceptScore W4377011059C2778886723 @default.
• W4377011059 hasConceptScore W4377011059C3018359032 @default.
• W4377011059 hasConceptScore W4377011059C3019800554 @default.
• W4377011059 hasConceptScore W4377011059C71924100 @default.
• W4377011059 hasFunder F4320309117 @default.
• W4377011059 hasIssue "4" @default.
• W4377011059 hasLocation W43770110591 @default.
• W4377011059 hasLocation W43770110592 @default.
• W4377011059 hasLocation W43770110593 @default.
• W4377011059 hasOpenAccess W4377011059 @default.
• W4377011059 hasPrimaryLocation W43770110591 @default.
• W4377011059 hasRelatedWork W1761397256 @default.
• W4377011059 hasRelatedWork W2098706915 @default.
• W4377011059 hasRelatedWork W2222828401 @default.
• W4377011059 hasRelatedWork W2438976023 @default.
• W4377011059 hasRelatedWork W2566351228 @default.
• W4377011059 hasRelatedWork W2911896204 @default.
• W4377011059 hasRelatedWork W3023502736 @default.
• W4377011059 hasRelatedWork W3112648508 @default.
• W4377011059 hasRelatedWork W4226373090 @default.
• W4377011059 hasRelatedWork W4294301186 @default.
• W4377011059 hasVolume "10" @default.
• W4377011059 isParatext "false" @default.
• W4377011059 isRetracted "false" @default.
• W4377011059 workType "article" @default.